Dr. Grey AI

Calcitonin Salmon

Peptide

Calcitonin salmon is a 32-amino acid peptide hormone analog used for postmenopausal osteoporosis and hypercalcemia. FDA-approved since 1975 as nasal spray (200 IU daily) and injection (100 IU daily). A-GRADE evidence: PROOF trial showed 33% reduction in vertebral fractures at 200 IU daily. A-GRADE for bone turnover marker reduction and acute fracture pain relief. B-GRADE for BMD increase and chronic bone pain. Has unique analgesic properties making it useful for acute osteoporotic fracture pain. Salmon calcitonin has 40-50x greater potency than human calcitonin. PRESCRIPTION ONLY - second-line osteoporosis treatment after bisphosphonates.

Quick Answer

What it is

Calcitonin salmon is a 32-amino acid peptide hormone analog used for postmenopausal osteoporosis and hypercalcemia. FDA-approved since 1975 as nasal spray (200 IU daily) and injection (100 IU daily).

Key findings

  • Grade A: Vertebral Fracture Risk (Osteoporosis)
  • Grade A: Bone Turnover Markers (Bone Health)
  • Grade A: Acute Fracture Pain (Osteoporosis)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Calcitonin Salmon

Quick Facts: Calcitonin Salmon

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:14
  • Grade A Findings:4
  • Grade B Findings:2
  • Key Effect:Osteoporosis
A4
B2
C3
D5
2 conditions Β· 14 outcomes

Detailed Outcomes

|
A
Vertebral Fracture Risk
PROOF trial showed 33% reduction in new vertebral fractures with 200 IU nasal spray (RR 0.67, P=0.03) over 5 years. 36% reduction in women with 1-5 prevalent fractures.
moderate↓Improves
A
Acute Fracture Pain
Multiple RCTs demonstrate significant analgesic effect in acute osteoporotic vertebral compression fractures, with reduced pain scores and analgesic requirements.
moderate↓Improves
B
Bone Mineral Density
Calcitonin produces modest increases in lumbar spine BMD, though effects are less pronounced than bisphosphonates or other antiresorptives.
small↑Improves
A
Bone Turnover Markers
Calcitonin reduces bone resorption markers through direct inhibition of osteoclast activity.
moderate↓Improves
A
Hypercalcemia
Calcitonin is FDA-approved for acute treatment of hypercalcemia, rapidly lowering serum calcium through inhibition of bone resorption.
large↓Improves
B
Chronic Bone Pain
Calcitonin provides pain relief in osteoporosis and other painful bone conditions through central and peripheral analgesic mechanisms.
moderate↓Improves
C
Liver Protection
9 preclinical studies support this finding. Primarily preclinical evidence.
moderate↑Improves
C
Anti-Cancer Activity
4 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
small↑Improves
C
GI Protection
3 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Kidney Function
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Blood Glucose Control
2 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves
D
Lipid Profile
2 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves
D
Safety/Tolerability
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Seizure Activity
2 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves

Research Citations (44)

Quantitative Analysis of Salmon Calcitonin Hydroxyapatite Nanoparticle Permeation to substantiate Non-Invasive Bone Targeting via Sublingual Delivery.
(2025)
PMID: 40102334
A trilayer microneedle patch for transdermal delivery of the peptide salmon calcitonin for osteoporosis therapy.
(2025)
PMID: 40845924
Tuning the double lipidation of salmon calcitonin to introduce a pore-like membrane translocation mechanism.
(2024)
PMID: 38713958
Composite Separable Microneedles for Transdermal Delivery and Controlled Release of Salmon Calcitonin for Osteoporosis Therapy.
(2023)
PMID: 36576723
Enhancing the gastrointestinal stability of salmon calcitonin through peptide stapling.
(2023)
PMID: 37186112
Examination of Effective Buccal Absorption of Salmon Calcitonin Using Cell-Penetrating Peptide-Conjugated Liposomal Drug Delivery System.
(2022)
PMID: 35210769
Involvement of nitric oxide pathway in the acute anticonvulsant effect of salmon calcitonin in rats.
(2022)
PMID: 35066437
Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures
(2021)
PMID: 34745472
The effect of salmon calcitonin against glutamate-induced cytotoxicity in the C6 cell line and the roles the inflammatory and nitric oxide pathways play.
(2021)
PMID: 34370176
Effects of Teriparatide versus Salmon Calcitonin Therapy for the Treatment of Osteoporosis in Asia: A Meta-analysis of Randomized Controlled Trials.
(2021)
PMID: 33109070

Related Peptides

Teriparatide (Forteo)

Peptide

2 shared conditions Β· 13 outcomes

Teriparatide (brand name Forteo) is a recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). It was FDA-approved in November 2002 as the first anabolic agent for osteoporosis treatment. Unlike antiresorptive drugs, teriparatide stimulates new bone formation. It is indicated for postmenopausal women and men with osteoporosis at high fracture risk, and for glucocorticoid-induced osteoporosis.

Romosozumab (Evenity)

Peptide

2 shared conditions Β· 11 outcomes

Romosozumab (Evenity) is a humanized monoclonal antibody that inhibits sclerostin, a key negative regulator of bone formation. FDA-approved in April 2019 for postmenopausal women with osteoporosis at high fracture risk. It has a unique dual mechanism: stimulating bone formation while reducing bone resorption. The FRAME and ARCH trials demonstrated significant reductions in vertebral and clinical fractures.

Denosumab (Prolia/Xgeva)

Peptide

2 shared conditions Β· 14 outcomes

Denosumab is a fully human monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor-ΞΊB ligand), the key mediator of osteoclast formation and activity. FDA-approved in 2010 for osteoporosis (Prolia, 60mg every 6 months) and bone metastases (Xgeva, 120mg monthly). The landmark FREEDOM trial demonstrated significant reductions in vertebral, hip, and nonvertebral fractures, with benefits sustained up to 10 years in extension studies.